TGF-β pathway is hyperactivated during breast cancer progression, making it an attractive therapeutic target.68 We have validated the inhibitory role of OVOL1 on TGF-β pathway transduction and TGF-β-induced EMT (Fig. 4), suggesting that restoration of OVOL1 expression may be an option for targeting the pro-oncogenic TGF-β signaling in breast cancer. This evidence concerns the gene OVOL1 and breast cancer.